About 50% of ductal breast carcinomas do not yield analysable karyotypes after short-term culturing. Comparison of the cytogenetic subset to the whole data set of tumors revealed that slightly hyperdiploid tumors, that is, with DNA index between 1.05 and 1.3, were underrepresented in tumors for which cytogenetic analysis was successful. The purpose of this study was to determine whether the pattern of chromosome imbalances in this subset differs from that generally reported. Comparative genomic hybridization (CGH) was used on 43 primary ductal breast carcinomas selected for slight hyperdiploidy. Microsatellite instability (MSI), TP53 mutation and expression were also investigated. All tumors were MSI negative. In all, 18 tumors (42%) presented mostly unbalanced chromosome rearrangements and DNA amplifications, with only few or no whole chromosome gains (WCG). This pattern of chromosome imbalances corresponds to that described in most breast tumors by previous cytogenetic and CGH analyses. It was associated with TP53 mutation in 17% of tumors. Another subset of 17 tumors (39%) displayed different and new features, characterized by recurrent gains of whole chromosomes 5, 7 and 8 with few chromosome rearrangements, rare DNA amplifications and no TP53 mutation. Eight tumors with as many rearrangements as WCG were left unclassified. We propose that, beside a major pathway characterized by multiple chromosome rearrangements, there is a minor pathway mainly characterized by WCG.
Introduction
Breast cancer is the most common malignancy among women. Cytogenetic and CGH analyses have been applied to a number of primary breast cancers and demonstrated a complex pattern of chromosome abnormalities that consists mostly in unbalanced rearrangements, associated with a strong tendency to endoreduplication resulting in aneuploidy (Dutrillaux et al., 1991) . Different histological types were identified but even among invasive ductal carcinomas, which represent the large majority of breast cancers, the heterogeneity of the clinical evolution and response to therapy suggests that several pathological entities exist. Classification of invasive ductal carcinomas into subtypes based on genetic (see for a review, Devilee and Cornelisse, 1994; Bieche and Lidereau, 1995) or cytogenetic (Dutrillaux et al., 1991; Hoglund et al., 2002; Teixeira et al., 2002) alterations has been proposed, but in spite of many attempts, it was not possible to draw any correlation between them.
In colorectal carcinoma, which is probably the most intensively studied human tumor, two distinct subsets of tumors are recognized. Early cytogenetic studies (Muleris et al., 1988 (Muleris et al., , 1990 showed that a large subset of tumors (70%), predominant in the distal colon, evolve through structural chromosome rearrangements leading to recurrent deletions, while another subset of diploid/ slightly hyperdiploid tumors (30%), prevalent in the proximal colon, exhibits no or few structural rearrangements but, rather, gains of whole chromosomes (Delattre et al., 1989; Muleris et al., 1990) . Over the past decade, evidence has accumulated to support the existence of these two subtypes of colorectal cancer. In most cases, the development process involves mutational inactivation of several tumor suppressor genes (Fearon and Vogelstein, 1990) , frequently exhibits gross aneuploidy, loss of heterozygosity at numerous loci and frequent TP53 alterations (see for a review Shackney and Shankey, 1997). These tumors are predominant in the distal colon. In the subset of right-sided diploid/ slightly hyperdiploid colorectal tumors, the underlying mechanism generating genetic aberrations frequently involves another pathway of tumorigenesis associated with microsatellite instability (MSI) Ionov et al., 1993; Lothe et al., 1993; Thibodeau et al., 1993) due to deficiency in the DNA mismatch repair system. Cytogenetic data showed that sporadic MSI tumors exhibit karyotypes with no or few chromosomal aberrations mostly constituted of whole chromosome gains (WCG) (Remvikos et al., 1995 . Sporadic MSI cancers represent a distinct entity with a specific profile of genetic changes and different clinical and pathological characteristics (review in Haydon and Jass, 2002) .
One limitation of cytogenetic analysis in solid tumors is their low proliferative capacities in vitro. In our hands, after 48-72 h cultures, chromosome analysis could be performed in about 50% of breast tumors. A flow cytometry analysis of DNA ploidy indicated that slightly hyperdiploid tumors, that is, with DNA index ranging from 1.05 to 1.3, were under-represented in tumors for which cytogenetic analysis was successful. Based on the two different chromosome subtypes described in colorectal tumors, we addressed the question as to whether a pattern with WCG and few structural changes could be found in slightly hyperdiploid breast tumors. We took advantage of the comparative genomic hybridization (CGH) analysis, which enables the detection of DNA copy number changes across the genome from a few micrograms of tumor DNA regardless of the mitotic activity of the tumor, and combined it with cytometry to characterize chromosomal imbalances in slightly hyperdiploid ductal breast carcinomas.
We suggest that two different chromosome patterns exist. In one, aneuploidy was almost exclusively a consequence of structural chromosome aberrations (SCA) associated with frequent DNA amplifications. In the other, aneuploidy was a consequence of numerical chromosome aberrations (NCA). The relationships of these patterns with MSI and TP53 alterations were investigated.
Results

Definition of tumors with SCA or NCA
It is well known that the process of tumoral evolution is accompanied with alterations of the karyotype that include both structural and numerical changes. CGH allows to distinguish both types of alterations. A uniform green or red CGH staining along a chromosome indicates a WCG or loss in the tumor, respectively, whereas partial gain or loss of chromosome material indicates that the chromosome underwent a structural rearrangement. Such chromosomes will be further designated as rearranged chromosomes (RC). If chromosome alterations accumulate in breast tumor cells at random, without any specificity for either WCG or RC, both types of aberrations should increase concurrently during tumor progression. In order to test this hypothesis, the number of WCG, RC and DNA amplifications were counted in each tumor (Table 1 ). It was found that the number of RC was not correlated with that of WCG (r ¼ À0.21, P ¼ 0.17). Thus, the increase of the number of RC does not parallel that of WCG during tumor progression (Figure 1 ). DNA amplifications accumulate concurrently with RC (r ¼ 0.7, Po0.001). On the contrary, WCG and DNA amplification are inversely correlated (r ¼ À0.37, P ¼ 0.013). This indicates that two subsets of tumors may be defined on the nature of the accumulating chromosomal changes.
Analysing the chromosome imbalances observed in the 43 tumors, it appeared that the most frequent imbalances, observed in 60% of tumors, were 1q and 16p gains and 16q deletions. Previous studies indicated that these imbalances likely resulted from isochromosomes 1q and t(1;16)(q10;p10), two frequent aberrations in breast carcinomas that were found to arise quite early during tumor progression Pandis et al., 1995; Tirkkonen et al., 1998) . Since these imbalances may be shared by most tumors as initial step, gains of chromosome 1q as well as imbalances of chromosomes 1q and 16 when associated were excluded from the count of RC, which led us to define a new parameter, the partial number of rearranged chromo- Table 2 . Chromosome imbalances observed in the NCA and SCA tumors are presented in Figure 2 . In NCA tumors, recurrent chromosome imbalances (425%) were gains of 1q, 16p, 7, 5 and 8 and losses of 16q and 22. Only one of these tumors showed subregional DNA amplifications. In SCA tumors, frequent losses involved chromosomes 16q, 8p, 11q distal and 17p and most frequent 2-qter, 3, 6, 7, 8q, 16p 1p35-pter, 8p, 11q, 16q, 17p, X 24 7, 16, 20, 22pter-q12 6q24-qter, 9p, 19 Figure 2 (Table 3) . Out of 18 SCA tumors, 11 (61%) had DNA amplification. They mapped to chromosome 11q13 (five cases), 11q14.3-q22 (three cases), 6q15-q23, 8q23 and 10p13-pter (two cases) and 15 other single chromosomal sites (Figure 2 ). DNA amplifications were significantly more frequent in SCA tumors (Po0.001) in which they correlated with the total number of aberrations (r ¼ 0.59, P ¼ 0.008).
Comparing the pattern of chromosome imbalances in SCA and NCA tumors, the frequent imbalances, 1q and 16p gains and 16q deletion, were common to both tumor types. Other recurrent chromosome imbalances were found to be more frequently associated with one tumor type, which defines consistent patterns of imbalances. Losses of 8p, 11q distal and 17p, 11q13 amplifications and gains of 8q, 17q and 19q were recurrent in SCA tumors, whereas trisomies of chromosomes 5, 7 and 8 and losses of 22 were more frequent in NCA tumors.
Considering the chromosomal imbalances in the eight unclassified tumors, it was found that cases 28 and 40 presented only imbalances involving chromosomes 1 and 16, and thus are likely to correspond to very early step in chromosome evolution before commitment to a NCA or SCA pathway. The other tumors had mixed characters.
Correlation of CGH features with clinicopathological data
No significant difference could be demonstrated between NCA and SCA tumors with regard to tumor size (T1 versus T2), tumor grade (I, II or III) estrogen/ progesterone receptor status ( þ versus À) and age (p50 years old versus 450 years old). Neither the number of RC nor that of WCG was correlated to the histological grading in NCA tumors or SCA tumors.
MSI status
We analysed allelic profiles of the Bat-25 and Bat-26 monomorphic markers to establish the MSI status of 29 breast tumors (13 NCA, 11 SCA and five undetermined tumors). Only normal alleles were found and all tumors were classified as MSI negative (not shown).
p53 immunochemical staining and TP53 mutational status
The p53 immunostaining was always nuclear, although some samples did exhibit minor cytoplasmic staining just above background. Two cases (no. 35 and 41) had more than 50% and one (no. 33) more than 10% positive nuclei and were scored as p53 positive. All three cases were SCA tumors. In a further four tumors, 1-5% of nuclei were stained, but these cases were classified as negative since they were below the threshold value of 10%.
In all, 38 tumors characterized by CGH (17 SCA, 15 NCA and six undetermined tumors) were screened for mutation detection in exons 4-9 of the TP53 gene by direct sequencing. Three tumors (8%) exhibited a mutation in TP53 (Table 4) . In case 41, a transversion T-G was observed in exon 5, resulting in a missense mutation at codon 176. In cases 35 and 42, there were deletions of 12 (exon 7) and 41 base pairs (exon 9), respectively, leading to frameshift mutations. The 41 bp deletion induced a stop codon at position 331 and the tumor harboring this deletion was negative for p53 staining. In the two other tumors, TP53 alterations were correlated with a strong p53 staining. All three cases with TP53 mutations were SCA tumors and were among those with the higher number of RC, including 17p13 deletion. (Pandis et al., 1995) . In our sample, trisomies were never found as the sole aberration. It should be noticed that since we analysed slightly hyperdiploid tumors, the NCA we referred to in NCA tumors were trisomies due to mitotic nondisjunction of individual chromosomes. This should be distinguished from aneuploidy following polyploidization, a frequent feature of breast tumors.
Two cytogenetic patterns of evolution in breast carcinomas
Tumors were classified upon a ratio between the WCG and the pRC. We chose a quite selective criterion, that is, more pRC than WCG to define SCA tumors and more WCG than pRC to define NCA tumors. It is relevant that the two subsets of tumors, which have only been separated on the nature of the chromosomal alterations, showed some specific imbalances. This demonstrates that concerted nonrandom chromosome rearrangements or gains occur in the SCA and NCA subset, respectively. For instance, DNA amplification, which was not considered for classification, was found almost exclusively in SCA tumors. Pathway of chromosome evolution involving WCG with few RC is not restricted to subsets of colorectal and breast carcinomas. It has been described in other tumor types, especially sarcomas such as Ewing sarcoma (Dutrillaux, 2000) . Indeed, in these tumors, besides the specific t(11;22) translocation, 1q duplication and trisomies of chromosomes 8 and 12 are reported to be the most frequent aberrations (see for a review Sandberg and Bridge, 2000) . A model of chromosomal evolution of breast carcinomas has been proposed (Dutrillaux et al., 1991) . It was suggested that structural unbalanced rearrangements and losses of entire chromosomes occur first, which give rise to hypodiploidy. Then, tumors would frequently undergo endoreduplication increasing their DNA content and set of chromosomes close to tetraploidy. Subsequent chromosomal losses associated with additional rearrangements would lead to hypotriploidy in the most advanced stages. CGH analysis of slightly hyperdiploid breast carcinomas gives support to this model and provides more details about the early stages of tumor progression (Figure 3) . The SCA tumors with few RC observed in our study might represent cytogenetically less advanced tumors, in which DNA losses induced by deletions are counter-balanced by the few chromosome arm gains and DNA amplifications, making these tumors slightly hyperdiploid. Our CGH study revealed that at least one other cytogenetic pathway exists. A fraction of tumors may evolve mainly through progressive entire chromosome gains without undergoing numerous chromosome rearrangements. Since SCA and NCA tumors Figure 3 Genetic pathways of evolution in ductal breast carcinomas. This scheme was established according to data from cytogenetics, flow cytometry (Dutrillaux et al., 1991) and CGH (this study). Black lines, pathway for tumors with SCA; hatched line, pathway for tumors with NCA; DI, DNA index; R, chromosome rearrangements and losses; A, DNA amplifications; E, endoreduplication; G, WCG Characterization of ductal breast carcinomas R Molist et al share some early occurring frequent chromosomal alterations, it suggests that they would initiate chromosomal evolution by a common pathway of primary imbalances ( þ 1q, þ 16p, À16q) before they evolve in specific pathways. This is also supported by the finding that two of our tumors (cases 28 and 40) presented these imbalances as sole aberrations. The NCA subset corresponds to 39% of the slightly hyperdiploid tumors and may represent 5-10% of all breast tumors. An intriguing question is why NCA tumors have not been previously identified in breast cancers analysed by classical cytogenetics. This may be attributed to a lower in vitro proliferative capacity of tumors with a DNA index between 1.05 and 1.3. Since chromosome analysis requires more tumor material than CGH, another hypothesis is that these tumors escaped chromosome analysis because only large size tumors can be used for cytogenetics, whereas our CGH sample mainly consists of small-sized tumors (data not shown). When we reassessed our cytogenetic sample in the light of our CGH findings, a few tumors with a typical NCA pattern could be identified (data not shown).
Cytogenetic pattern of evolution and TP53 and MSI status
Whereas MSI in colorectal neoplasms is well characterized, data on breast cancer are still inconsistent with a reported MSI rate ranging from 0 to 50% (Paulson et al., 1996; Shaw et al., 1996; Anbazhagan et al., 1999; Murata et al., 2002) . Such discrepancy could be linked to the histological type of tumors analysed or/and the number and sensitivity of the markers used. In our study, 29 ductal carcinomas were assessed for MSI and all were found to be MSI negative. The markers used, Bat-25 and Bat-26, are two monomorphic markers that had previously been found to be altered in various cancer types, including breast cancer (Walsh et al., 1998; Zhou et al., 1998) . Thus, unlike in colorectal carcinomas, chromosome gains pathway is not associated with MSI in breast carcinomas.
In our sample, TP53 mutations and/or overexpression were found in four tumors, all from the SCA subset. Thus in breast carcinomas, TP53 mutations occur in tumors with primarily structural abnormalities, as described in colorectal carcinomas. Compared to the mutation rate of 20-30% reported in breast cancers (Soussi et al., 2000; Olivier et al., 2002) , the incidence of TP53 mutations is similar in SCA tumors (17%), but significantly lower (0/17) in NCA tumors (Po0.05). The pattern of TP53 alterations including two frameshift mutations is uncommon, but because of the small size of our sample, no definite conclusion could be drawn.
An important question is that of the molecular mechanisms underlying the SCA and NCA tumors. The molecular basis of chromosome number instability remains largely unknown. Since segregation of chromosomes during mitosis involves different cellular processes, such as chromosome condensation, sister chromatids cohesion/separation, centrosome/microtubule formation and requires an efficient mitotic spindle checkpoint, defects in any of these steps may lead to numerical chromosome instability (see for a review Jallepalli and Lengauer, 2001 ). The molecular basis of chromosome structure instability is also unknown. One hypothesis is that rearrangements arise in cells that enter mitosis before double-strand breaks are repaired; the genes implicated being those involved in double-strand break repair. However, other mechanisms such as telomere erosion, DNA hypomethylation and dysfunction of p53 may exist, permitting the growth of cells that have sustained chromosome translocation, deletion and amplification events (Georgiades et al., 1999; Soulie et al., 1999) . It remains to establish whether the underlying rate of numerical and structural chromosome alterations is different in the two groups of tumors or whether the observed chromosome patterns are simply a consequence of different selective pressures. Scoring of chromosome instability in colorectal tumors suggests that the higher rate of rearrangements observed in one subset of tumors is due to the preferential selection of RC, rather than to a higher occurrence of structural abnormalities (Muleris and Dutrillaux, 1996) . Thus, the selective conditions in NCA breast tumors might counter select cells with unbalanced chromosome rearrangements, even though they arise at equal rate in both pathways. An interesting observation was made by Bernardino et al. (1997) , who described an unusual clonal evolution in a breast carcinoma. The primary tumor was hyperdiploid with several WCG, whereas in the metastasis, most cells shared several rearrangements and overexpressed p53. Since all karyotypes had in common some aberrations, this suggested a clonal evolution that began with an NCA pathway and then turned into an SCA pathway in a clone that colonized the metastasis. It could be hypothesized that such change is related with p53 overexpression that made the cells permissive for deletions and rearrangements. Such change in evolutive pathway could account for the mixed chromosomal alterations observed in unclassified cases. It should be of interest to determine which genes, beside TP53, are associated with cytogenetic pathways.
Materials and methods
Tumor specimens
In all, 43 primary ductal breast carcinomas (30 biopsies and 13 fine-needle aspirates) with a DNA index between 1. 05 and 1.3 were used for CGH analysis. There were 42 infiltrating ductal carcinomas and one ductal carcinoma in situ. The distribution of tumor grades (according to the SBR histological typing) was grade I (11 cases), grade II (14 cases) and grade III (nine cases) for the 34 tumors in which information was available. The mean age of the patients was 60 years (range 25-94 years).
Cytometric DNA assessments
The DNA ploidy status was evaluated by flow cytometry. Cell preparation, staining procedure and internal standardization were based on methods described previously . Part of each tumor nuclei preparation was used for evaluation of DNA ploidy on a FACSCAN instrument (Becton-Dickinson, Franklin Lakes, NJ, USA) using the Modfit software. Only the tumors with a DNA histogram exhibiting a distinct G0/G1 peak in a DNA index range between 1.05 and 1.3 and corresponding to at least 80% of all analysed nuclei were retained, to ensure that the cell sample contained mainly cancerous material. When these two conditions were fulfilled, the rest of the stained nuclei suspension was frozen and stored until DNA was extracted for CGH analysis.
CGH and digital image analysis
Tumor and reference DNA (normal female donor) were extracted using the Qiagen kit. CGH was performed according to the previous protocol (Kallioniemi et al., 1994) . Briefly, tumor and reference DNA were labeled with FITC-12-dUTP (DuPont NEN, Boston MA, USA) and Texas red-5-dUTP (DuPont NEN, Boston, MA, USA) respectively. Labeled normal and tumor DNA (400 ng each) with 10 mg of Cot-1 DNA (Gibco Life Technologies Inc., Gaithersburg, MD, USA) were hybridized onto normal metaphase cells. Images were obtained with a cooled charge-coupled device camera (Sensys, Photometrics Ltd., Tucson, AZ, USA) mounted onto an automated fluorescence microscope (Leica DMRB, Braunschweig, Germany) equipped with three band pass filters arranged in an automated filter wheel. CGH analysis of each sample was carried out from about 10 well-hybridized metaphases using QUIPS software (Vysis Inc., Downers Grove, IL, USA). Chromosome imbalances were analysed on the basis of the mean color ratio profile deviating from the balanced value (green to red ¼ 1). The cutoff values of 0.90 for losses and 1.10 for gains were defined from the analysis of negative controls, whereby two differently labeled normal DNAs were hybridized against each other. DNA amplifications were defined as subregional high-level copy number increases with a green to red fluorescence ratio 41.3.
MSI assays
In total, 29 tumors were analysed to determine the MSI status using Bat-25 and Bat-26 (Hoang et al., 1997) . Tumor DNA (10 ng) template was amplified with 20 pmol of each primer. PCR products were labeled by [a- 32 P]dCTP during the amplification reaction, separated by electrophoresis in 6% denaturing polyacrylamide gels and visualized by autoradiography (Remvikos et al., 1995) . The presence or absence of MSI was based on the detection of length alterations in both Bat-25 and Bat-26 markers. Three colonic cell lines were used as MSI þ (LOVO, HCT116) and MSIÀ (LS513) controls.
p53 immunochemical staining
Frozen sections from the 30 surgical specimens and 13 cytocentrifuged fine-needle samples were analysed for p53 immunoreactivity using the N-terminal-specific DO-7 monoclonal antibody (Dako Corp., Carpinteria, CA, USA) as described previously (Lesec et al., 1997) . The primary antibody was used diluted to 1/250 and the binding was revealed with a biotin/peroxidase two-step method (Vectastain, Vector, Burlingame, CA, USA).
TP53 sequencing
Exons 4-9 of TP53 were screened for mutation detection using the following primers sets: exon 4 (S5 0 -CTGGTCCTCTG ACTGCTCTT-3 0 , A5 0 -ATACGGCCAGGCATTGAAGT-3 0 ); exons 5 and 6 (S5 0 -CACTTGTGCCCTGACTTTCAACT CTGT-3 0 , A5 0 -ACCCTTAACCCCTCCTCCCAGAGA-3 0 ); exon 7 proximal (S5 0 -TTGCCACAGGTCTCCCCAA-3 0 , A5 0 -GTGGCTCCTGACCTGGAGTC-3 0 ); and exons 7 distal, 8 and 9 (S5 0 -CTGTACCACCATCCACTACA-3 0 , A5 0 -CATTT TGAGTGTTAGACTGGAA-3 0 ). PCR reactions were performed using 50 ng of tumor DNA template in 50 ml reaction mixture containing 20 pmol of each primer, 12.5 nmol of dNTP, 2.5 U of Taq DNA polymerase and 1 Â Taq buffer (Q Biogen, Illkirch, France). Direct sequencing of the PCR product was performed by fluorescent dye-labeled dideoxynucleotides using ABI Prism BigDye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All mean values are indicated7the standard error of the mean. Mann-Whitney U-test was used to compare the mean number of RC and WCG in the two subsets of tumors and the mean number of RC according to histological grading. w 2 test was used to compare the association between clinicopathologic variables, DNA amplification, TP53 mutations and NCA and SCA subsets. Correlations were tested using the Spearman's test. All statistical tests were two-sided. All analyses were conducted using the GrapfPad Prism software (GrapfPad Software Inc., San Diego, CA, USA).
